177 related articles for article (PubMed ID: 35581229)
1. Conventional and digital Ki67 evaluation and their correlation with molecular prognosis and morphological parameters in luminal breast cancer.
Pons L; Hernández-León L; Altaleb A; Ussene E; Iglesias R; Castillo A; Rodríguez-Martínez P; Castella E; Quiroga V; Felip E; Cirauqui B; Margelí M; Fernández PL
Sci Rep; 2022 May; 12(1):8176. PubMed ID: 35581229
[TBL] [Abstract][Full Text] [Related]
2. Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early estrogen receptor-positive breast cancer.
Tan AC; Li BT; Nahar K; Danieletto S; Fong ES; Currer T; Parasyn A; Middleton P; Wong H; Smart D; Rutovitz JJ; McCloud P; Hughes TM; Marx GM
Asia Pac J Clin Oncol; 2018 Apr; 14(2):e161-e166. PubMed ID: 28960862
[TBL] [Abstract][Full Text] [Related]
3. Evaluation oncotype DX
Lashen A; Toss MS; Fadhil W; Oni G; Madhusudan S; Rakha E
Histopathology; 2023 Apr; 82(5):755-766. PubMed ID: 36631400
[TBL] [Abstract][Full Text] [Related]
4. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
Milburn M; Rosman M; Mylander C; Tafra L
Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
[TBL] [Abstract][Full Text] [Related]
5. Low correlation between Ki67 assessed by qRT-PCR in Oncotype Dx score and Ki67 assessed by Immunohistochemistry.
Selmani Z; Molimard C; Overs A; Bazan F; Chaigneau L; Dobi E; Meneveau N; Mansi L; Paillard MJ; Meynard G; Viot J; Algros MP; Borg C; Feugeas JP; Pivot X; Prétet JL; Curtit E
Sci Rep; 2022 Mar; 12(1):3617. PubMed ID: 35256657
[TBL] [Abstract][Full Text] [Related]
6. Relationship of Oncotype Dx score with tumor grade, size, nodal status, proliferative marker Ki67 and Nottingham Prognostic Index in early breast cancer tumors in Saudi Population.
Durrani S; Al-Mushawa F; Heena H; Wani T; Al-Qahtani A
Ann Diagn Pathol; 2021 Apr; 51():151674. PubMed ID: 33360027
[TBL] [Abstract][Full Text] [Related]
7. Correlation of the Ki67 Working Group prognostic risk categories with the Oncotype DX Recurrence Score in early breast cancer.
Patel R; Hovstadius M; Kier MW; Moshier EL; Zimmerman BS; Cascetta K; Jaffer S; Sparano JA; Tiersten A
Cancer; 2022 Oct; 128(20):3602-3609. PubMed ID: 35947048
[TBL] [Abstract][Full Text] [Related]
8. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
[TBL] [Abstract][Full Text] [Related]
9. Discordance of Oncotype DX scores in synchronous bilateral and unilateral multifocal breast cancers.
Wang J; Chen H; Koenig J; Wu Y; Bedrosian I; Arun B; Ding Q; Khazai L; Resetkova E; Huo L; Sneige N; Albarracin C
Breast Cancer Res Treat; 2024 Jan; 203(1):73-83. PubMed ID: 37751078
[TBL] [Abstract][Full Text] [Related]
10. In ER-Positive, HER2-Negative Breast Cancers, HER2 mRNA Levels Correlate Better with Clinicopathologic Features and Oncotype DX Recurrence Score than HER2 Immunohistochemistry.
Tyburski H; Karakas C; Finkelman BS; Turner BM; Zhang H; Hicks DG
Lab Invest; 2024 Mar; 104(3):100309. PubMed ID: 38135156
[TBL] [Abstract][Full Text] [Related]
11. The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer.
Thakur SS; Li H; Chan AMY; Tudor R; Bigras G; Morris D; Enwere EK; Yang H
PLoS One; 2018; 13(1):e0188983. PubMed ID: 29304138
[TBL] [Abstract][Full Text] [Related]
12. Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancer.
Varga Z; Sinn P; Fritzsche F; von Hochstetter A; Noske A; Schraml P; Tausch C; Trojan A; Moch H
PLoS One; 2013; 8(3):e58483. PubMed ID: 23505515
[TBL] [Abstract][Full Text] [Related]
13. A simple immunohistochemical bio-profile incorporating Bcl2 curbs those cases of invasive breast carcinoma for which an Oncotype Dx characterization is needed.
Ceccarelli C; De Leo A; Chieco P; Zamagni C; Zamagni A; Rubino D; Taffurelli M; Santini D
PLoS One; 2019; 14(6):e0217937. PubMed ID: 31158261
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Estrogen receptors, Progesterone receptors and HER2-neu immunohistochemistry results in breast cancer with those of Oncotype Dx.
Sughayer MA; Alhassoon S; Sughayer HM
Ann Diagn Pathol; 2020 Aug; 47():151556. PubMed ID: 32592992
[TBL] [Abstract][Full Text] [Related]
15. Concordance of the molecular subtype classification between core needle biopsy and surgical specimen in primary breast cancer.
Pölcher M; Braun M; Tischitz M; Hamann M; Szeterlak N; Kriegmair A; Brambs C; Becker C; Stoetzer O
Arch Gynecol Obstet; 2021 Sep; 304(3):783-790. PubMed ID: 33585986
[TBL] [Abstract][Full Text] [Related]
16. Predicting oncotype DX recurrence scores using locally available immunohistochemical markers: experience in a district general hospital.
Humphris K; Stephenson J; Kumaraswamy V
J Clin Pathol; 2023 Apr; 76(4):252-255. PubMed ID: 34903609
[TBL] [Abstract][Full Text] [Related]
17. Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer.
Morales Murillo S; Gasol Cudos A; Veas Rodriguez J; Canosa Morales C; Melé Olivé J; Vilardell Villellas F; Sanchez Guzman DR; Iglesias Martínez E; Salud Salvia A
Breast; 2021 Apr; 56():35-41. PubMed ID: 33601299
[TBL] [Abstract][Full Text] [Related]
18. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q
J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107
[TBL] [Abstract][Full Text] [Related]
19. Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing?
Allison KH; Kandalaft PL; Sitlani CM; Dintzis SM; Gown AM
Breast Cancer Res Treat; 2012 Jan; 131(2):413-24. PubMed ID: 21369717
[TBL] [Abstract][Full Text] [Related]
20. The Prognostic Significance of the Oncotype DX Recurrence Score in T
Wang M; Wu K; Zhang P; Zhang M; Ding A; Chen H
Ann Surg Oncol; 2019 May; 26(5):1227-1235. PubMed ID: 30456680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
